Control
Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies.
Nov 27 |
Ensovibep for COVID-19: real-time meta analysis of 2 studies | |
| Significantly lower risk is seen for hospitalization. One study shows significant benefit. Meta analysis using the most serious outcome reported shows 47% [-108‑87%] lower risk, without reaching statistical significance. Early .. | ||
Feb 6 |
et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2025.02.002 | Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial |
| 28% lower mortality (p=0.16) and 11% lower combined mortality/hospitalization (p=0.47). Analysis of 2,311 hospitalized COVID-19 patients from four randomized controlled trials (ACTIV-3/TICO) showing no significant difference in long-term mortality with sotrovimab, amubarvimab/romlusevimab, tixagevimab-cilgavimab, or ensovibep. | ||
May 3 2024 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofae233 | The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study |
| 89% lower mortality (p=0.06), 78% fewer combined hospitalization/ER visits (p=0.02), 87% lower hospitalization (p=0.01), and 87% improvement (p=0.01). RCT 407 mild to moderate COVID-19 outpatients showing faster viral clearance, lower risk of hospitalization/ER visits, and shorter time to sustained recovery with ensovibep treatment (75/225/600mg single infusion). There were 2 COVID-19 r.. | ||
Aug 9 2022 |
et al., Annals of Internal Medicine, doi:10.7326/M22-1503 | Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 |
| 28% lower mortality (p=0.16), 11% lower combined mortality/hospitalization (p=0.47), 6% improved recovery (p=0.55), and 7% higher hospital discharge (p=0.46). RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg. Long-term results are reported in [Mourad] | ||
Nov 16 2021 |
, Press Release | Molecular partners provides update from ACTIVE-3 global clinical study of ensovibep in patients hospitalized with COVID-19 |
| News release reporting that ensovibep was terminated for futility in ACTIV-3. 470 patients had been randomized. | ||
Feb 3 2021 |
et al., bioRxiv, doi:10.1101/2021.02.03.429164 | Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants |
| In silico, in vitro, and hamster study of ensovibep, a DARPin candidate that can engage all three units of the spike protein trimer to inhibit ACE2 interaction, showing efficacy for common variants, and efficacy comparable to casirivimab/.. | ||